Johnson & Johnson Earnings Preview: Pharma Is Where The Party Is

Given the recent Ebola outbreak in West Africa, the company has accelerated the development of vaccine which may be available for human trials by early 2015. These developments suggest that Johnson & Johnson is becoming more centered around its growing pharmaceutical business. We believe that its upcoming third quarter results will demonstrate the same. We expect strong growth in the pharma segment driven by Olysio and Zytiga when the company reports its Q3 2014 earnings on October 14th.